Compare Quest Diagnostics Inc (DGX) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Teucrium Soybean Fund — how do they compare? Quest Diagnostics Inc trades at $204.9 (market cap $22.80B), while Teucrium Soybean Fund trades at $25.44. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | SOYB | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.02 | $25.36 |
52-Week Low | $166.42 | $21.07 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SOYB trades at $25.33, up 0.64% on the day, with a bullish technical outlook from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, and recent news highlights potential tailwinds from agricultural trade developments, including China's pledge to buy $17 billion of U.S. crops annually through 2028, which could benefit related sectors.
The stock's upside is supported by positive technical momentum and sector-specific catalysts, though the absence of fundamental data limits valuation clarity. Risks include reliance on agricultural market stability and potential volatility from commodity price swings, requiring careful assessment of upcoming earnings and guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
